Imanixil (also known as HOE-402) was developed as a potent cholesterol-lowering compound, which inhibits VLDL production, and consequently attenuates atherosclerosis development. This drug participated in phase I clinical trial for the treatment of hyperlipidemia, however, this study was discontinued.

Tiflorex (also known as (+)-Flutiorex) is a phenylalkylamine derivative patented by Synthelabo S. A. as an anorectic agent. Tiflorex acts as a central nervous system stimulant form amphetamine class with little effect on pulse rate, sleep, or mood. In preclinical models, Tiflorex provoked a dose-dependent reduction in the consumption of the protein-rich diet and a reduction in the consumption of the protein-poor diet.

Teopranitol, a coronary vasodilator that was studied for the treatment of the acute myocardial ischemia. Animal experiments have shown that this compound stimulated the release of prostacyclin (PGI2)-like antiplatelet activity. However, the development of teopranitol was discontinued.

Belarizine was studied as a cerebral vasodilator.